Fortrea Holdings Reports 1% Revenue Growth to $2.72 Billion, Net Loss of $986.2 Million

Fortrea Holdings Inc. reported a modest increase in revenue for the fiscal year ended December 31, 2025, reaching $2.72 billion, a 1.0% rise from $2.70 billion in 2024. This growth was primarily driven by a 0.8% increase in organic revenues, alongside a favorable foreign currency translation impact of 0.2%. The clinical pharmacology segment contributed significantly to this revenue growth, although it was partially offset by a decline in clinical development revenues due to a shift in project complexity and duration. The company recorded a net loss of $986.2 million, which included a substantial goodwill impairment charge of $797.9 million related to its Clinical Development reporting unit.

In terms of operational metrics, Fortrea's backlog stood at $7.7 billion as of December 31, 2025, reflecting anticipated future revenue from business awards. The company’s workforce comprised approximately 14,300 employees, with operations spanning around 100 countries. The company has also made strategic moves, including the sale of its Enabling Services Segment for $340 million, which closed in the second quarter of 2024. This divestiture was part of a broader strategy to streamline operations and focus on core clinical services.

Fortrea's financial performance was impacted by rising direct costs, which increased by 2.7% to $2.22 billion, accounting for 81.5% of total revenues. This rise was attributed to higher pass-through costs and stock compensation expenses. Conversely, selling, general, and administrative expenses saw a significant decrease of 18.6%, totaling $456.4 million, primarily due to reduced transition service agreement costs. The company’s interest expenses also decreased by 26.2% to $91.4 million, reflecting a reduction in debt levels.

Looking ahead, Fortrea's management expressed optimism about future growth, citing an expected increase in R&D investments from pharmaceutical and biotechnology companies, which could drive demand for its services. The company is focused on enhancing its operational efficiency and expanding its market share in high-growth therapeutic areas, including oncology and rare diseases. However, it remains cautious about potential risks, including market volatility and regulatory changes that could impact its operations and financial performance.